These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

325 related items for PubMed ID: 32129111

  • 1. Experts' opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: a further help for human reproduction and beyond.
    Facchinetti F, Appetecchia M, Aragona C, Bevilacqua A, Bezerra Espinola MS, Bizzarri M, D'Anna R, Dewailly D, Diamanti-Kandarakis E, Hernández Marín I, Kamenov ZA, Kandaraki E, Laganà AS, Monastra G, Montanino Oliva M, Nestler JE, Orio F, Ozay AC, Papalou O, Pkhaladze L, Porcaro G, Prapas N, Soulage CO, Stringaro A, Wdowiak A, Unfer V.
    Expert Opin Drug Metab Toxicol; 2020 Mar; 16(3):255-274. PubMed ID: 32129111
    [Abstract] [Full Text] [Related]

  • 2. Inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: now and the future.
    Laganà AS, Myers SH, Forte G, Naem A, Krentel H, Allahqoli L, Alkatout I, Unfer V.
    Expert Opin Drug Metab Toxicol; 2024 Mar; 20(1-2):61-72. PubMed ID: 38226638
    [Abstract] [Full Text] [Related]

  • 3. Inositols in Polycystic Ovary Syndrome: An Overview on the Advances.
    Facchinetti F, Unfer V, Dewailly D, Kamenov ZA, Diamanti-Kandarakis E, Laganà AS, Nestler JE, Soulage CO, Group of 'Inositol in PCOS and Reproduction'.
    Trends Endocrinol Metab; 2020 Jun; 31(6):435-447. PubMed ID: 32396844
    [Abstract] [Full Text] [Related]

  • 4. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone.
    Nordio M, Proietti E.
    Eur Rev Med Pharmacol Sci; 2012 May; 16(5):575-81. PubMed ID: 22774396
    [Abstract] [Full Text] [Related]

  • 5. Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach.
    Laganà AS, Garzon S, Casarin J, Franchi M, Ghezzi F.
    Trends Endocrinol Metab; 2018 Nov; 29(11):768-780. PubMed ID: 30270194
    [Abstract] [Full Text] [Related]

  • 6. Reflections on inositol(s) for PCOS therapy: steps toward success.
    Nestler JE, Unfer V.
    Gynecol Endocrinol; 2015 Jul; 31(7):501-5. PubMed ID: 26177098
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients.
    Monastra G, Unfer V, Harrath AH, Bizzarri M.
    Gynecol Endocrinol; 2017 Jan; 33(1):1-9. PubMed ID: 27898267
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols.
    Sortino MA, Salomone S, Carruba MO, Drago F.
    Front Pharmacol; 2017 Jan; 8():341. PubMed ID: 28642705
    [Abstract] [Full Text] [Related]

  • 11. The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome.
    Dinicola S, Chiu TT, Unfer V, Carlomagno G, Bizzarri M.
    J Clin Pharmacol; 2014 Oct; 54(10):1079-92. PubMed ID: 25042908
    [Abstract] [Full Text] [Related]

  • 12. Inositols in the ovaries: activities and potential therapeutic applications.
    Laganà AS, Forte G, Bizzarri M, Kamenov ZA, Bianco B, Kaya C, Gitas G, Alkatout I, Terzic M, Unfer V.
    Expert Opin Drug Metab Toxicol; 2022 Feb; 18(2):123-133. PubMed ID: 35472446
    [Abstract] [Full Text] [Related]

  • 13. Inositols in PCOS.
    Kamenov Z, Gateva A.
    Molecules; 2020 Nov 27; 25(23):. PubMed ID: 33260918
    [Abstract] [Full Text] [Related]

  • 14. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios.
    Nordio M, Basciani S, Camajani E.
    Eur Rev Med Pharmacol Sci; 2019 Jun 27; 23(12):5512-5521. PubMed ID: 31298405
    [Abstract] [Full Text] [Related]

  • 15. Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome.
    Unfer V, Porcaro G.
    Expert Rev Clin Pharmacol; 2014 Sep 27; 7(5):623-31. PubMed ID: 24898153
    [Abstract] [Full Text] [Related]

  • 16. Breakthroughs in the Use of Inositols for Assisted Reproductive Treatment (ART).
    Facchinetti F, Espinola MSB, Dewailly D, Ozay AC, Prapas N, Vazquez-Levin M, Wdowiak A, Unfer V, Expert Group on Inositols in Preclinical and Clinical Research.
    Trends Endocrinol Metab; 2020 Aug 27; 31(8):570-579. PubMed ID: 32418772
    [Abstract] [Full Text] [Related]

  • 17. Inositol's and other nutraceuticals' synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives.
    Paul C, Laganà AS, Maniglio P, Triolo O, Brady DM.
    Gynecol Endocrinol; 2016 Jun 27; 32(6):431-8. PubMed ID: 26927948
    [Abstract] [Full Text] [Related]

  • 18. Bye-bye chiro-inositol - myo-inositol: true progress in the treatment of polycystic ovary syndrome and ovulation induction.
    Galletta M, Grasso S, Vaiarelli A, Roseff SJ.
    Eur Rev Med Pharmacol Sci; 2011 Oct 27; 15(10):1212-4. PubMed ID: 22165685
    [Abstract] [Full Text] [Related]

  • 19. The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial.
    Colazingari S, Treglia M, Najjar R, Bevilacqua A.
    Arch Gynecol Obstet; 2013 Dec 27; 288(6):1405-11. PubMed ID: 23708322
    [Abstract] [Full Text] [Related]

  • 20. Update on the combination of myo-inositol/d-chiro-inositol for the treatment of polycystic ovary syndrome.
    Lete I, Martínez A, Lasaga I, Centurión E, Vesga A.
    Gynecol Endocrinol; 2024 Dec 27; 40(1):2301554. PubMed ID: 38239032
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.